Ladies and Gentlemen,

First patient randomization and commencement of dosing was on November 11, 2015. It is now May 11, 2016 so we are at 6-months into the dosing in the BETonMACE trial for those first patients. We are entering unchartered territory since ASSURE (6-month trial) was their longest trial previous to BETonMACE. If I remember the BETonMACE study design correctly, patients were going to be dosed for an average of 18 months. Those entereing the study early would be dosed for 24 months; those entering the study later would be dosed for 12 months; works out to an average of 18 months.

BearDownAZ